**8. References**


Based on all of the above mentioned properties, there are two competing hypothesis of OPP liposome formulation – breast cancer cell interaction, which still need further experimental validation. Either OPP liposome formulations with low cholesterol concentration are able to deliver OPP into breast cancer cells by fusing with plasma membrane of breast cancer cells, due to liposome membrane properties, or alkylphospholipids whether in free or micellar form insert with high affinity into cholesterol containing target membranes (cells) as long as liposomal carriers contain low amounts of cholesterol. Once the remaining liposomal carriers have cholesterol concentration above around 50 mol% the remaining alkylphospholipids are stabilized in liposomes and do not interact with cells anymore. In this way liposomes serve as a reservoir capable of releasing alkylphospholipids and

Arndt, D., Zeisig, R., Eue, I., Sternberg, B., & Fichtner, I. (1997). Antineoplastic activity of

Arndt, D., Zeisig, R., Fichtner, I., Teppke, A.D., & Fahr, A. (1999). Pharmacokinetics of

Arsov, Z., Urbančič, I., Garvas, M., Biglino, D., Ljubetič, A., Koklič, T., & Štrancar, J. (2011).

Batista, U., Garvas, M., Nemec, M., Schara, M., Veranic, P., & Koklic, T. (2010). Effects of

Busto, J.V., Del Canto-Janez, E., Goni, F.M., Mollinedo, F., & Alonso, A. (2008). Combination

effects of the drug. *J Chem Biol,* Vol. 1, No. 1-4, (Nov), pp. 89-94, 1864-6158 Busto, J.V., Sot, J., Goñi, F.M., Mollinedo, F., & Alonso, A. (2007). Surface-active properties of

Carrasco, M.P., Jimenez-Lopez, J.M., Segovia, J.L., & Marco, C. (2008).

Chapman, D., Owens, N.F., Phillips, M.C., & Walker, D.A. (1969). Mixed monolayers of

Chen, K., Morse, P.D., 2nd, & Swartz, H.M. (1988). Kinetics of enzyme-mediated reduction

in HepG2 cells. *FEBS J,* Vol. 275, No. 8, (Apr), pp. 1675-86, 1742-464X Carrasco, S., & Merida, I. (2007). Diacylglycerol, when simplicity becomes complex. *Trends* 

*Biochem Sci,* Vol. 32, No. 1, (Jan), pp. 27-36, 0968-0004

No. 3, (Sep 1), pp. 477-84, 0006-3002

*Breast Cancer Res Treat,* Vol. 43, No. 3, (May), pp. 237-46, 0167-6806

sterically stabilized alkylphosphocholine liposomes in human breast carcinomas.

sterically stabilized hexadecylphosphocholine liposomes versus conventional liposomes and free hexadecylphosphocholine in tumor-free and human breast carcinoma bearing mice. *Breast Cancer Res Treat,* Vol. 58, No. 1, (Nov), pp. 71-80,

Fluorescence microspectroscopy as a tool to study mechanism of nanoparticles delivery into living cancer cells. *Biomed Opt Express,* Vol. submited for review, No.

different detachment procedures on viability, nitroxide reduction kinetics and plasma membrane heterogeneity of V-79 cells. *Cell Biol Int,* Vol. 2, No. 8, (Jun), pp.

of the anti-tumour cell ether lipid edelfosine with sterols abolishes haemolytic side

the antitumour ether lipid 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine (edelfosine). *Biochimica et Biophysica Acta (BBA) - Biomembranes,* Vol. 1768, No. 7, pp.

Hexadecylphosphocholine interferes with the intracellular transport of cholesterol

phospholipids and cholesterol. *Biochim Biophys Acta,* Vol. 183, No. 3, pp. 458-65,

of lipid soluble nitroxide spin labels by living cells. *Biochim Biophys Acta,* Vol. 943,

preventing side effect associated with high alkylphospholipid concentrations.

**8. References** 

0167-6806

pp. 2083-2095, 2156-7085

663-8, 1095-8355

1855-60, 0005-2736

0006-3002


Interaction of Alkylphospholipid Formulations with Breast Cancer

*Medicine,* Vol. Krakow, Poland, 4.-7. October 2010

303, 1878-5875

6393-9, 0022-2623

1779-87, 1476-5594

No. 1-2, pp. 87-95, 0167-6806

(May), pp. 2423-33, 1520-6017

Vol. 93, No. 8, (Oct), pp. 2688-96, 0006-3495

Cells in the Context of Anticancer Drug Development 381

Lucas, L., Hernandez-Alcoceba, R., Penalva, V., & Lacal, J.C. (2001). Modulation of

transduction. *Anticancer Drug Des,* Vol. 10, No. 5, (Jul), pp. 411-25, 0266-9536 Marco, C., Jimenez-Lopez, J.M., Rios-Marco, P., Segovia, J.L., & Carrasco, M.P. (2009).

Mravljak, J., Podlipec, R., Koklič, T., Pečar, S., & Šentjurc, M. (2010). Interaction of spin-

Mravljak, J., Zeisig, R., & Pecar, S. (2005). Synthesis and biological evaluation of spin-labeled

Munoz-Martinez, F., Torres, C., Castanys, S., & Gamarro, F. (2008). The anti-tumor

*Biophysica Acta-Biomembranes,* Vol. 1778, No. 2, (Feb), pp. 530-40, 0005-2736 Naundorf, H., Rewasowa, E.C., Fichtner, I., Buttner, B., Becker, M., & Gorlich, M. (1992).

Nieto-Miguel, T., Fonteriz, R.I., Vay, L., Gajate, C., Lopez-Hernandez, S., & Mollinedo, F.

Nieto-Miguel, T., Gajate, C., & Mollinedo, F. (2006). Differential targets and subcellular

Pabst, G., Hodzic, A., Strancar, J., Danner, S., Rappolt, M., & Laggner, P. (2007).

Pearson, G., Robinson, F., Beers Gibson, T., Xu, B.E., Karandikar, M., Berman, K., & Cobb,

cells. *J Biol Chem,* Vol. 281, No. 21, (May 26), pp. 14833-40, 0021-9258 Orthmann, A., Zeisig, R., Koklic, T., Sentjurc, M., Wiesner, B., Lemm, M., & Fichtner, I.

phospholipase D by hexadecylphosphorylcholine: a putative novel mechanism for its antitumoral activity. *Oncogene,* Vol. 20, No. 9, (Mar 1), pp. 1110-7, 0950-9232 Maly, K., Uberall, F., Schubert, C., Kindler, E., Stekar, J., Brachwitz, H., & Grunicke, H.H.

(1995). Interference of new alkylphospholipid analogues with mitogenic signal

Hexadecylphosphocholine alters nonvesicular cholesterol traffic from the plasma membrane to the endoplasmic reticulum and inhibits the synthesis of sphingomyelin in HepG2 cells. *Int J Biochem Cell Biol,* Vol. 41, No. 6, (Jun), pp. 1296-

labeled derivatives of a cancerostatic alkylphospholipid, perifosine, with model and cell membranes. *VIIIth International Workshop on EPR(ESR) in Biology and* 

alkylphospholipid analogs. *Journal of Medicinal Chemistry,* Vol. 48, No. 20, (Oct), pp.

alkylphospholipid perifosine is internalized by an ATP-dependent translocase activity across the plasma membrane of human KB carcinoma cells. *Biochimica Et* 

Characterization of two human mammary carcinomas, MT-1 and MT-3, suitable for in vivo testing of ether lipids and their derivatives. *Breast Cancer Res Treat,* Vol. 23,

(2007). Endoplasmic reticulum stress in the proapoptotic action of edelfosine in solid tumor cells. *Cancer Res,* Vol. 67, No. 21, (Nov 1), pp. 10368-78, 1538-7445 Nieto-Miguel, T., Gajate, C., Gonzalez-Camacho, F., & Mollinedo, F. (2008). Proapoptotic

role of Hsp90 by its interaction with c-Jun N-terminal kinase in lipid rafts in edelfosine-mediated antileukemic therapy. *Oncogene,* Vol. 27, No. 12, (Mar 13), pp.

localization of antitumor alkyl-lysophospholipid in leukemic versus solid tumor

(2010). Impact of membrane properties on uptake and transcytosis of colloidal nanocarriers across an epithelial cell barrier model. *J Pharm Sci,* Vol. 99, No. 5,

Rigidification of neutral lipid bilayers in the presence of salts. *Biophysical Journal,*

M.H. (2001). Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. *Endocr Rev,* Vol. 22, No. 2, (Apr), pp. 153-83, 0163-769X Rahmani, M., Reese, E., Dai, Y., Bauer, C., Payne, S.G., Dent, P., Spiegel, S., & Grant, S.

(2005). Coadministration of histone deacetylase inhibitors and perifosine


Heesbeen, E.C., Verdonck, L.F., Hermans, S.W., van Heugten, H.G., Staal, G.E., & Rijksen, G.

Hochhuth, C.H., Vehmeyer, K., Eibl, H., & Unger, C. (1992). Hexadecylphosphocholine

Jimenez-Lopez, J.M., Carrasco, M.P., Marco, C., & Segovia, J.L. (2006).

Kaufmann-Kolle, P., Berger, M.R., Unger, C., & Eibl, H. (1996). Systemic administration of

Kiss, Z., & Crilly, K.S. (1997). Alkyl lysophospholipids inhibit phorbol ester-stimulated

Koklic, T., Pirs, M., Zeisig, R., Abramovic, Z., & Sentjurc, M. (2005). Membrane switch

Koklic, T., Sentjurc, M., & Zeisig, R. (2010). Determination of the amount of micelles in

Koklic, T., Zeisig, R., & Sentjurc, M. (2008). Interaction of alkylphospholipid liposomes with

Kyriakis, J.M., & Avruch, J. (2001). Mammalian mitogen-activated protein kinase signal

Limatola, C., Schaap, D., Moolenaar, W.H., & van Blitterswijk, W.J. (1994). Phosphatidic acid

method. *J Liposome Res,* Vol. 21, No. 1, (Mar), pp. 1-8, 1532-2394

*Cancer Ther,* Vol. 2, No. 11, (Nov), pp. 1093-103, 1535-7163

in HL-60 cells. *FEBS Lett,* Vol. 290, No. 1-2, (Sep 23), pp. 231-4, 0014-5793 Hilgard, P., Klenner, T., Stekar, J., Nossner, G., Kutscher, B., & Engel, J. (1997). D-21266, a

No. 3, (Mar), pp. 442-6, 0959-8049

No. 8, (Apr 14), pp. 1114-21, 0006-2952

83, No. 1-2, (Feb), pp. 130-8, 1098-8823

*Res,* Vol. 12, No. 4, (Nov), pp. 335-52, 0898-2104

2, (Jul 28), pp. 313-7, 0014-5793

No. 2, (Apr), pp. 807-69, 0031-9333

No. (Dec 15), pp. 1001-8, 0264-6021

2621-31, 0950-9232

(1991). Alkyllysophospholipid ET-18-OCH3 acts as an activator of protein kinase C

new heterocyclic alkylphospholipid with antitumour activity. *Eur J Cancer,* Vol. 33,

induces interferon-gamma secretion and expression of GM-CSF mRNA in human mononuclear cells. *Cell Immunol,* Vol. 141, No. 1, (Apr 15), pp. 161-8, 0008-8749 Jendrossek, V., Muller, I., Eibl, H., & Belka, C. (2003). Intracellular mediators of

erucylphosphocholine-induced apoptosis. *Oncogene,* Vol. 22, No. 17, (May 1), pp.

Hexadecylphosphocholine disrupts cholesterol homeostasis and induces the accumulation of free cholesterol in HepG2 tumour cells. *Biochem Pharmacol,* Vol. 71,

alkylphosphocholines. Erucylphosphocholine and liposomal hexadecylphosphocholine. *Adv Exp Med Biol,* Vol. 416, No. pp. 165-8, 0065-2598 Kim, Y.L., Im, Y.J., Ha, N.C., & Im, D.S. (2007). Albumin inhibits cytotoxic activity of

lysophosphatidylcholine by direct binding. *Prostaglandins Other Lipid Mediat,* Vol.

phospholipase D activity and DNA synthesis in fibroblasts. *FEBS Lett,* Vol. 412, No.

hypothesis. 1. Cell density influences lateral domain structure of tumor cell membranes. *J Chem Inf Model,* Vol. 45, No. 6, (Nov-Dec), pp. 1701-7, 1549-9596 Koklic, T., Sentjurc, M., & Zeisig, R. (2002). The influence of cholesterol and charge on the

membrane domains of alkylphospholipid liposomes as studied by EPR. *J Liposome* 

alkylphospholipid liposome formulations with electron paramagnetic resonance

MT-3 breast-cancer cells depends critically on cholesterol concentration. *Biochimica et Biophysica Acta (BBA) - Biomembranes,* Vol. 1778, No. 12, pp. 2682-9, 0005-2736 Kondapaka, S.B., Singh, S.S., Dasmahapatra, G.P., Sausville, E.A., & Roy, K.K. (2003).

Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. *Mol* 

transduction pathways activated by stress and inflammation. *Physiol Rev,* Vol. 81,

activation of protein kinase C-zeta overexpressed in COS cells: comparison with other protein kinase C isotypes and other acidic lipids. *Biochem J,* Vol. 304 ( Pt 3),


Interaction of Alkylphospholipid Formulations with Breast Cancer

pp. 295-6, 0378-584X

Cells in the Context of Anticancer Drug Development 383

Ueda, A., Nagase, S., Yokoyama, H., Tada, M., Noda, H., Ohya, H., Kamada, H., Hirayama,

Unger, C., Sindermann, H., Peukert, M., Hilgard, P., Engel, J., & Eibl, H. (1992).

van Blitterswijk, W.J., van der Meer, B.W., & Hilkmann, H. (1987). Quantitative

polarization. *Biochemistry,* Vol. 26, No. 6, (Mar 24), pp. 1746-56, 0006-2960 van Blitterswijk, W.J., & Verheij, M. (2008). Anticancer alkylphospholipids: Mechanisms of

van der Luit, A.H., Vink, S.R., Klarenbeek, J.B., Perrissoud, D., Solary, E., Verheij, M., & van

van Dijk, M.C., Muriana, F.J., de Widt, J., Hilkmann, H., & van Blitterswijk, W.J. (1997).

Vink, S.R., van der Luit, A.H., Klarenbeek, J.B., Verheij, M., & van Blitterswijk, W.J. (2007).

Vrablic, A.S., Albright, C.D., Craciunescu, C.N., Salganik, R.I., & Zeisel, S.H. (2001). Altered

Wenzel, J., Zeisig, R., & Fichtner, I. (2009). Inhibition of metastasis in a murine 4T1 breast

*Pharmaceutical Design,* Vol. 14, No. 21, (Jul), pp. 2061-74, 1381-6128

*Cancer Therapeutics,* Vol. 6, No. 8, pp. 2337-45, 1535-7163

Vol. 20, No. 1, (Jan), pp. 1-5, 0301-472X

74, No. 10, (Nov 15), pp. 1456-65, 0006-2952

*Res,* Vol. 53, No. 4, (Feb 15), pp. 711-3, 0008-5472

*Metastasis,* Vol. 27, No. 1, pp. 25-34, 1573-7276

cancer patients. *Prog Exp Tumor Res,* Vol. 34, No. pp. 153-9, 0079-6263 van Blitterswijk, W.J., van der Luit, A.H., Veldman, R.J., Verheij, M., & Borst, J. (2003).

*Biochem J,* Vol. 369, No. Pt 2, (Jan 15), pp. 199-211, 0264-6021

A., & Koyama, A. (2003). Importance of renal mitochondria in the reduction of TEMPOL, a nitroxide radical. *Mol Cell Biochem,* Vol. 244, No. 1-2, (Feb), pp. 119-24, Unger, C., & Eibl, H. (1991). Hexadecylphosphocholine: Preclinical and the first clinical results of a new antitumor drug. *Lipids,* Vol. 26, No. 12, pp. 1412-7, 0024-4201 Unger, C., Eibl, H., Breiser, A., von Heyden, H.W., Engel, J., Hilgard, P., Sindermann, H.,

Peukert, M., & Nagel, G.A. (1988). Hexadecylphosphocholine (D 18506) in the topical treatment of skin metastases: a phase-I trial. *Onkologie,* Vol. 11, No. 6, (Dec),

Hexadecylphosphocholine in the topical treatment of skin metastases in breast

Ceramide: second messenger or modulator of membrane structure and dynamics?

contributions of cholesterol and the individual classes of phospholipids and their degree of fatty acyl (un)saturation to membrane fluidity measured by fluorescence

action, cellular sensitivity and resistance, and clinical prospects. *Current* 

Blitterswijk, W.J. (2007). A new class of anticancer alkylphospholipids uses lipid rafts as membrane gateways to induce apoptosis in lymphoma cells. *Molecular* 

Involvement of phosphatidylcholine-specific phospholipase C in platelet-derived growth factor-induced activation of the mitogen-activated protein kinase pathway in Rat-1 fibroblasts. *J Biol Chem,* Vol. 272, No. 17, (Apr 25), pp. 11011-6, 0021-9258 Vehmeyer, K., Eibl, H., & Unger, C. (1992). Hexadecylphosphocholine stimulates the colony-

stimulating factor-dependent growth of hemopoietic progenitor cells. *Exp Hematol,*

Lipid rafts and metabolic energy differentially determine uptake of anti-cancer alkylphospholipids in lymphoma versus carcinoma cells. *Biochem Pharmacol,* Vol.

mitochondrial function and overgeneration of reactive oxygen species precede the induction of apoptosis by 1-O-octadecyl-2-methyl-rac-glycero-3-phosphocholine in p53-defective hepatocytes. *FASEB J,* Vol. 15, No. 10, (Aug), pp. 1739-44, 0892-6638 Wagner, B.A., Buettner, G.R., & Burns, C.P. (1993). Increased generation of lipid-derived and

ascorbate free radicals by L1210 cells exposed to the ether lipid edelfosine. *Cancer* 

cancer model by liposomes preventing tumor cell-platelet interactions. *Clin Exp* 

synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species. *Cancer Res,* Vol. 65, No. 6, (Mar 15), pp. 2422-32, 0008-5472


Rakotomanga, M., Loiseau, P.M., & Saint-Pierre-Chazalet, M. (2004).

*Biophysica Acta-Biomembranes,* Vol. 1661, No. 2, (Mar), pp. 212-8, 0005-2736 Rakotomanga, M., Saint-Pierre-Chazalet, M., & Loiseau, P.M. (2005). Alteration of fatty acid

Rizzo, M.A., Shome, K., Watkins, S.C., & Romero, G. (2000). The recruitment of Raf-1 to

Ruiter, G.A., Verheij, M., Zerp, S.F., & van Blitterswijk, W.J. (2001). Alkyl-lysophospholipids

Ruiter, G.A., Zerp, S.F., Bartelink, H., van Blitterswijk, W.J., & Verheij, M. (1999). Alkyl-

Sobottka, S.B., & Berger, M.R. (1992). Assessment of antineoplastic agents by MTT assay:

Stopar, D., Strancar, J., Spruijt, R.B., & Hemminga, M.A. (2006). Motional restrictions of

Strancar, J., Koklic, T., & Arsov, Z. (2003). Soft picture of lateral heterogeneity in

Strancar, J., Koklic, T., Arsov, Z., Filipic, B., Stopar, D., & Hemminga, M.A. (2005). Spin label

Strassheim, D., Shafer, S.H., Phelps, S.H., & Williams, C.L. (2000). Small cell lung carcinoma

Swartz, H.M., Sentjurc, M., & Morse, P.D., 2nd (1986). Cellular metabolism of water-soluble

*and Modeling,* Vol. 45, No. 2, (Mar-Apr), pp. 394-406, 1549-9596

*Cancer Res,* Vol. 65, No. 6, (Mar 15), pp. 2422-32, 0008-5472

*Chemotherapy,* Vol. 49, No. 7, (Jul), pp. 2677-86, 0066-4804

*Oncol Biol Phys,* Vol. 49, No. 2, (Feb 1), pp. 415-9, 0360-3016

lipids. *Apoptosis,* Vol. 4, No. 6, (Dec), pp. 419-27, 1360-8185

Vol. 30, No. 5, pp. 385-93, 0344-5704

No. 9, (Nov), pp. 3341-8, 0006-3495

1538-7445 (Electronic) 0008-5472 (Linking)

23911-8, 0021-9258

0022-2631

pp. 2730-6, 0008-5472

synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species.

Hexadecylphosphocholine interaction with lipid monolayers. *Biochimica Et* 

and sterol metabolism in miltefosine-resistant Leishmania donovani promastigotes and consequences for drug-membrane interactions. *Antimicrobial Agents and* 

membranes is mediated by direct interaction with phosphatidic acid and is independent of association with Ras. *J Biol Chem,* Vol. 275, No. 31, (Aug 4), pp.

as anticancer agents and enhancers of radiation-induced apoptosis. *Int J Radiat* 

lysophospholipids activate the SAPK/JNK pathway and enhance radiationinduced apoptosis. *Cancer Res,* Vol. 59, No. 10, (May 15), pp. 2457-63, 0008-5472 Smets, L.A., Van Rooij, H., & Salomons, G.S. (1999). Signalling steps in apoptosis by ether

partial underestimation of antiproliferative properties. *Cancer Chemother Pharmacol,*

membrane proteins: A site-directed spin labeling study. *Biophysical Journal,* Vol. 91,

biomembranes. *Journal of Membrane Biology,* Vol. 196, No. 2, (Nov 15), pp. 135-46,

EPR-based characterization of biosystem complexity. *Journal of Chemical Information* 

exhibits greater phospholipase C-beta1 expression and edelfosine resistance compared with non-small cell lung carcinoma. *Cancer Res,* Vol. 60, No. 10, (May 15),

nitroxides: effect on rate of reduction of cell/nitroxide ratio, oxygen concentrations and permeability of nitroxides. *Biochim Biophys Acta,* Vol. 888, No. 1, (Aug 29), pp. 82-90, Tazzari, P.L., Tabellini, G., Ricci, F., Papa, V., Bortul, R., Chiarini, F., Evangelisti, C.,

Martinelli, G., Bontadini, A., Cocco, L.*, et al.* (2008). Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor Perifosine in acute myelogenous leukemia cells. *Cancer Res,* Vol. 68, No. 22, (Nov 15), pp. 9394-403,


**Part 5** 

**Breast Cancer Cell Interaction,** 

**Invasion and Metastasis** 

